Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of 14C-ETX2514 (Durlobactam) in Healthy Males
NCT04018950Phase 1Completed
- Sponsor
- Entasis Therapeutics
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durlobactam in Acinetobacter baumannii-calcoaceticus complex infection, sponsored by Entasis Therapeutics. Primary endpoints: Cumulative urinary recovery of total radioactivity, Cumulative fecal recovery of total radioactivity and 4 more. Started Jun 2019; status: completed.
02
Drugs
durlobactam
03
Conditions
Acinetobacter baumannii-calcoaceticus complex infection
Beyond the preview
Go deeper on NCT04018950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018950.